#CQDMQuantumLeapProgram

[otiskeene]

Variational AI Announces Generative AI Project With Merck

With funding from the CQDM Quantum Leap program, Variational AI, the creator of the EnkiTM generative artificial intelligence (AI) platform for drug development, has announced a joint effort with Merck Research Labs. Merck has agreed to be an early adopter of the EnkiTM Platform in order to test the platform's potential to produce new small molecules based on targets that Merck has selected.

By utilizing generative AI, the EnkiTM Platform is intended to expedite the drug discovery process. EnkiTM is a foundation model that can produce new lead-like structures that are synthesizable, selective, and unique. It generates original graphics in response to predetermined cues, much like previous generative AI models like DALL-E and Midjourney. With EnkiTM, molecules are described using the language of chemistry through a sequence of prompts based on a target product profile (TPP). Afterwards, EnkiTM quickly produces structures that satisfy the TPP, giving chemists a variety of lead-like compounds that are synthesizable, selective, and available for further analysis.

AI is being more and more used in medication discovery; many businesses are using their own proprietary models to find and create new products. By offering a platform where chemists can submit their TPPs and receive innovative structures in a matter of days, variational AI seeks to streamline the process and expedite the lead optimization process.

The CEO of Variational AI, Handol Kim, announced with delight that Merck will be using the EnkiTM Platform in early access. Through this partnership, Merck will be able to evaluate Enki's capacity to produce innovative small molecules that are customized to their particular targets. Kim underscored the value of incorporating AI into drug discovery and said that chemists who prefer not to create their own generative AI models might use EnkiTM as a substitute.

Read More - bit.ly/3vQyH3M